NEOG vs QGEN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: QGEN is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NEOG and QGEN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NEOG and QGEN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and support animal health. It operates in two segments: Food Safety (roughly 70% of sales after the 3M Food Safety acquisition), which tests for pathogens, spoilage organisms, toxins, and allergens, and Animal Safety, which sells veterinary instruments, diagnostics, disinfectants, rodent and insect control products, and life science reagents. The Food Safety segment is now the larger contributor and the strategic core following the transformative 3M deal.

Full NEOG guide

QIAGEN makes the consumables and instruments labs use to collect, stabilize, purify, and analyze DNA and RNA, then extends into molecular diagnostics through platforms like QIAstat-Dx (syndromic infectious-disease testing), QuantiFERON (latent tuberculosis detection), and QIAcuity digital PCR. It serves more than 500,000 customers across molecular diagnostics, applied testing, academic research, and pharma, with a portfolio of 500-plus proprietary consumables and automated workflows. The December 2025 acquisition of Parse Biosciences pushed its Sample technologies franchise into single-cell analysis, one of five strategic growth pillars the company is steering toward its 2028 goals.

Full QGEN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• NEOG drivers: Recurring food safety testing demand; Deleveraging and portfolio focus.
• QGEN drivers: QIAstat-Dx syndromic testing; Sample technologies and single-cell.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. For QGEN, quantiFERON tuberculosis sales have been a persistent drag and are exposed to competition and testing-volume swings.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick NEOG if you believe its drivers more; QGEN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NEOG and QGEN guides.

NEOG. Neogen posts positive adjusted EBITDA (~$175M target) but recent GAAP results show net losses, largely from 3M acquisition amortization. The gap between adjusted and reported figures, plus elevated debt, is why valuation is contested despite a multi-billion-dollar market cap on roughly $855M of sales.

QGEN. Q1 2026 reported sales rose about 2 percent to roughly $492 million while constant-currency sales fell about 1 percent, and management guided full-year sales to about $2.1 billion and adjusted EPS to about $2.43, both below prior consensus. At a roughly $8.3 billion market cap the stock carries a mid-teens forward P/E, valuing it as a steady compounder rather than a high-growth name. The valuation reflects durable consumable revenue and margin discipline against low-single-digit organic growth.

Headline figures (approximate, July 2026): NEOG shows revenue (fy2026 guidance) ~$857-860M, adjusted ebitda (fy2026) ~$175M, q3 fy2026 revenue ~$211M, q3 fy2026 net loss ~-$17M; QGEN shows revenue (q1 2026) ~$492M, revenue (fy2026 guidance) ~$2.1B, adjusted eps (fy2026 guidance) ~$2.43, market cap ~$8.3B.

NEOG and QGEN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined NEOG and QGEN exposure against your real portfolio. It is not an investment adviser.